Cargando…
Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models
BACKGROUND: Although quite challenging, neuroprotective therapies in ischemic stroke remain an interesting strategy to counter mechanisms of ischemic injury and reduce brain tissue damage. Among potential neuroprotective drug, cyclin-dependent kinases (CDK) inhibitors represent interesting therapeut...
Autores principales: | Menn, Bénédicte, Bach, Stéphane, Blevins, Teri L., Campbell, Mark, Meijer, Laurent, Timsit, Serge |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920814/ https://www.ncbi.nlm.nih.gov/pubmed/20711428 http://dx.doi.org/10.1371/journal.pone.0012117 |
Ejemplares similares
-
The Cdk5 inhibitor Roscovitine increases LTP induction in corticostriatal synapses
por: Miranda-Barrientos, Jorge, et al.
Publicado: (2014) -
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD
por: Bukanov, Nikolay O., et al.
Publicado: (2012) -
Genetic and pharmacological inhibition of Cdk1 provides neuroprotection towards ischemic neuronal death
por: Marlier, Quentin, et al.
Publicado: (2018) -
Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells
por: Le Roy, Lucas, et al.
Publicado: (2021) -
Several Human Cyclin-Dependent Kinase Inhibitors, Structurally Related to Roscovitine, As New Anti-Malarial Agents
por: Houzé, Sandrine, et al.
Publicado: (2014)